EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Recent Advances in the Development of Adenovirus-Vectored Vaccines for Parasitic Infections

Cal Koger-Pease, Dilhan J Perera iD, Momar Ndao

Pharmaceuticals · 22.02.2023 · 16 (3) · 334

DOI: 10.3390/ph16030334 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 22.02.2023. Verfasst von Cal Koger-Pease und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Experimental Medicine, McGill University, Montreal, QC H3A 3J1, Canada. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 236 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Public Health Agency of Canada/National Microbiology Laboratory, Foundation of the McGill University Health Centre, Research Institute of the McGill University Health Centre.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vaccines against parasites have lagged centuries behind those against viral and bacterial infections, despite the devastating morbidity and widespread effects of parasitic diseases across the globe. One of the greatest hurdles to parasite vaccine development has been the lack of vaccine strategies able to elicit the complex and multifaceted immune responses needed to abrogate parasitic persistence. Viral vectors, especially adenovirus (AdV) vectors, have emerged as a potential solution for complex disease targets, including HIV, tuberculosis, and parasitic diseases, to name a few. AdVs are highly immunogenic and are uniquely able to drive CD8+ T cell responses, which are known to be correlates of immunity in infections with most protozoan and some helminthic parasites. This review presents recent developments in AdV-vectored vaccines targeting five major human parasitic diseases: malaria, Chagas disease, schistosomiasis, leishmaniasis, and toxoplasmosis. Many AdV-vectored vaccines have been developed for these diseases, utilizing a wide variety of vectors, antigens, and modes of delivery. AdV-vectored vaccines are a promising approach for the historically challenging target of human parasitic diseases.

Schlagwörter

Stichwörter der Autor:innen

adenovirus vaccineshelminthparasitesprotozoavaccine vector

Autor:innen und Institutionen

  • Division of Experimental Medicine, McGill University, Montreal, QC H3A 3J1, Canada.
  • Infectious Diseases and Immunity in Global Health (IDIGH) Program, Research Institute of the McGill University Health Centre, Montreal, QC H4A 3J1, Canada.
  • Department of Microbiology and Immunology, McGill University, Montreal, QC H3A 0G4, Canada.
  • National Reference Centre for Parasitology, Research Institute of McGill University Health Centre, Montreal, QC H4A 3J1, Canada.

ORCID-Profile: Dilhan J Perera

Förderung

  • Public Health Agency of Canada/National Microbiology Laboratory
  • Foundation of the McGill University Health Centre
  • Research Institute of the McGill University Health Centre
  • R. Howard Webster Foundation

Zitieren

APA

Koger-Pease, C., Perera, D. J., & Ndao, M. (2023). Recent Advances in the Development of Adenovirus-Vectored Vaccines for Parasitic Infections. Pharmaceuticals, 16(3), 334. https://doi.org/10.3390/ph16030334

Vancouver

Koger-Pease C, Perera DJ, Ndao M. Recent Advances in the Development of Adenovirus-Vectored Vaccines for Parasitic Infections. Pharmaceuticals. 2023;16(3):334. doi:10.3390/ph16030334

BibTeX
@article{KogerPease2023,
  author = {Koger-Pease, Cal and Perera, Dilhan J and Ndao, Momar},
  title = {Recent Advances in the Development of Adenovirus-Vectored Vaccines for Parasitic Infections},
  journal = {Pharmaceuticals},
  year = {2023},
  volume = {16},
  number = {3},
  pages = {334},
  doi = {10.3390/ph16030334}
}
Kostenlos starten →